Company Overview

For personal use only IHL-675A Lung Inflammation Problem Inflammation is a major contributing factor to a range of lung diseases. Many patients don't respond, or experience side-effects, with current drug treatments. Solution IHL-675A targets two components of the inflammatory pathway by combining two anti-inflamamtory drugs, CBD and hydroxychloroquine sulfate. Incannex has demonstrated that CBD and hydroxychloroquine sulfate synergistically reduce inflammatory markers in an animal model of lung inflammation. Clinical development status Asset IHL-675A Inflammatory Lung Disease* Preclinical FDA Incannex Pre-IND Phase 1 CT # IHL-675A Australian clinical trial investigating safety and pharmacokinetics in healthy volunteers. FDA IND Addressable Market FDA Phase 2 US$50.4B 3.7% Projected global COPD & asthma drugs market by 2022 Projected annual growth rate from 2016 to 2022³ FDA Phase 3 Lead Assets ..00000000 (3) https://www.alliedmarketresearch.com/asthma-COPD-drug-market Anticipated Milestones Complete Phase 1 CT Open FDA IND Phase 2 CT 2023 Investor Presentation 21

View entire presentation